Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-controlled trial of terpene-enriched high-CBD cannabis oil in children with autism spectrum disorder
MOH_2025-04-21_014042Phase 2Not yet recruiting
- Sponsor
- Bazelet Nehushtan
- Start
- Mar 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BCANN ASD28 in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Bazelet Nehushtan. Primary endpoint: Change in ABC-I score at week 8. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
BCANN ASD28
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on MOH_2025-04-21_014042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-21_014042.